The Osteoprotegerin - Von Willebrand Factor Complex: Protagonist Or Bystander In Atherothrombosis?

Elod Nagy

doi:10.1515/amma-2016-0012

.blurhash-client-img { display: none !important; }

The Osteoprotegerin - Von Willebrand Factor Complex: Protagonist Or Bystander In Atherothrombosis?

Acta Marisiensis - Seria Medica

Volume 62 (2016): Issue 2 (June 2016)

By: Elod Nagy

Open Access

|May 2016

Abstract

Two important cardiovascular risk factors, osteoprotegerin and Von Willebrand Factor form complex in endothelial cells and in circulating blood. The pathophysiological role of the complex is unknown. We give a brief review of the relevant literature and confront it with some of our recent findings regarding the OPG-VWF correlation.

References

1. Bryckaert M, Rosa JP, Denis CV, Lenting PJ- Of von Willebrand factor and platelets. Cell Mol Life Sci. 2015;72:307-326.10.1007/s00018-014-1743-8
Search in Google Scholar
2. McKinnon TA, Chion AC, Millington AJ, Lane DA, Laffan MA- N-linked glycosylation of VWF modulates its interaction with ADAMTS13. Blood. 2008;111:3042-3049.10.1182/blood-2007-06-095042
Search in Google Scholar
3. Reid P, Holen I – Pathophysiological role of osteoprotegerin (OPG). European Journal of Cell Biology. 2009;88:1-17.10.1016/j.ejcb.2008.06.004
Search in Google Scholar
4. Shahbazi S, Lenting PJ, Fribourg C, Terraube V, Denis CV, Christophe OD - Characterization of the interaction between von Willebrand factor and osteoprotegerin. J Thromb Haemost. 2007;5:1956-1962.10.1111/j.1538-7836.2007.02681.x
Search in Google Scholar
5. Zannettino AC, Holding CA, Diamond P et al - Osteoprotegerin (OPG) is localized to the Weibel-Palade bodies of human vascular endothelial cells and is physically associated with von Willebrand factor. J Cell Physiol. 2005, 204:714-723.10.1002/jcp.20354
Search in Google Scholar
6. Rutten B, Maseri A, Cianflone D - Plasma levels of active Von Willebrand factor are increased in patients with first ST-segment elevation myocardial infarction: A multicenter and multiethnic study. Eur Heart J Acute Cardiovasc Care. 2015;4:64-74.10.1177/2048872614534388
Search in Google Scholar
7. Hosbond SE, Poulsen TS, Diederichsen ACP, Nybo M, Rasmussen LM, Mickley H- Osteoprotegerin as a marker of atherosclerosis: A systematic update. Scandinavian Cardiovascular Journal. 2012;46:203-211.10.3109/14017431.2012.685491
Search in Google Scholar
8. Ali Z, Ellington AA, Mosley TH, Jr., Kullo IJ: Association of serum osteoprotegerin with ankle-brachial index and urine albumin: creatinine ratio in African-Americans and non-Hispanic whites. Atherosclerosis. 2009;206:575-580.10.1016/j.atherosclerosis.2009.03.032
Search in Google Scholar
9. Vinholt PJ, Overgaard M, Diederichsen AC, Mickley H, Poulsen TS, Sand NP, Nybo M, Rasmussen LM: An ELISA for the quantitation of von Willebrand factor: osteoprotegerin complexes in plasma. Thromb Res. 2013,131:396-400.10.1016/j.thromres.2013.03.001
Search in Google Scholar

Articles in this issue

DOI: https://doi.org/10.1515/amma-2016-0012 | Journal eISSN: 2668-7763 | Journal ISSN: 2668-7755

Journal RSS Feed

Language: English

Page range: 289 - 290

Submitted on: Jan 22, 2016

Accepted on: Jan 24, 2016

Published on: May 20, 2016

Published by: University of Medicine, Pharmacy, Science and Technology of Targu Mures

In partnership with: Paradigm Publishing Services

Publication frequency: 4 issues per year

Keywords:

osteoprotegerin,

Von Willebrand Factor

Related subjects:

Medicine,

Clinical medicine,

Clinical medicine, other

© 2016 Elod Nagy, published by University of Medicine, Pharmacy, Science and Technology of Targu Mures
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Volume 62 (2016): Issue 2 (June 2016)